Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician.
Détails
Etat: Public
Version: Final published version
Licence: CC BY-NC 4.0
ID Serval
serval:BIB_0FEB39DECCD1
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician.
Périodique
Infection and drug resistance
ISSN
1178-6973 (Print)
ISSN-L
1178-6973
Statut éditorial
Publié
Date de publication
2023
Peer-reviewed
Oui
Volume
16
Pages
1087-1097
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Publication Status: epublish
Résumé
Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-hospital morbidity and mortality. The limited number of antifungal drug classes and the emergence of multi-resistant Candida species, such as Candida auris and some Candida glabrata isolates, is concerning. However, recent advances in antifungal drug development provide promising perspectives for the therapeutic approach of IC. Notably, three novel antifungal agents, currently in Phase II/III clinical trials, are expected to have an important place for the treatment of IC in the future. Rezafungin is a novel echinocandin with prolonged half-life. Ibrexafungerp and fosmanogepix are two first-in-class antifungal drugs with broad spectrum activity against Candida spp., including C. auris and echinocandin-resistant species. These novel antifungal agents also represent interesting alternative options because of their acceptable oral bioavailability (ibrexafungerp and fosmanogepix) or their large interdose interval (once weekly intravenous administration for rezafungin) for prolonged and/or outpatient treatment of complicated IC. This review discusses the potential place of these novel antifungal drugs for the treatment of IC considering their pharmacologic properties and their preclinical and clinical data.
Mots-clé
Candida, T-2307, antifungal therapy, candidemia, fosmanogepix, ibrexafungerp, oteseconazole, rezafungin, tetrazoles
Pubmed
Web of science
Open Access
Oui
Création de la notice
13/03/2023 17:25
Dernière modification de la notice
21/03/2023 8:08